Concurrent gemcitabine and cisplatin combined with 3D conformal radiotherapy for stage III non-small cell lung cancer

Chinese-German Journal of Clinical Oncology

Volumn 8, Issue 3, 2009, Pages 156-159

  Ke, Qinghua ^a   Fu, Guoquan ^a   Bian, Yaowu ^a   Jiang, Daiwen ^a   Yang, Jiyuan ^a  

^a Second Hospital of Jingzhou   (China)

Author keywords

Chemotherapy; Cisplatin; Gemcitabine; Non small cell lung cancer (NSCLC); Prognosis; Three dimensional conformal radiotherapy (3DCRT)

Indexed keywords

CISPLATIN; GEMCITABINE; UNCLASSIFIED DRUG; ZEFEI;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 63649138031     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-008-0164-2     Document Type: Article

References (11)

1. Lau DH, Ryu JK, Gandara DR, et al. Twice-weekly paclitaxel and radiation for stage III non-small cell lung caner. Semin Oncol, 1997, 24 (4 Suppl 12): S12-106-S12-109.
2. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-smallcell lung cancer. J Clin Oncol, 1999, 17: 2692-2699.
3. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC. RTOG 9410. Proc Am Soc Clin Oncol, 2003, 22: 621.
4. van Putten JW, Price A, van der Leest AH, et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res, 2003, 9: 2472-2477.
5. Tang ZQ, chief-editor. Modern oncology. The second edition. Shanghai: Publishing Press of Shanghai Medical University, 2003. 450.
6. Pang HM, Xu N, Geng BQ, chief editors. The diagnosis and treatment strategy of oncology internal medicine. Shanghai: Shanghai Science & Technology Publishing Press, 2002. 41.
7. Dong ZW, Gu XZ, chief editors. Clinical oncology. Beijing: People's Health Press, 2002. 272.
8. Miao JB, Zhang RY, Shen WJ, et al. In vitro gemcitabine radiosensitization of human non-small cell lung caner cell line A549 (wtp53). Chin J Radiat Oncol (Chinese), 2004, 13: 325-328.
9. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIAbulky N2 and stage IIIB non small cell lung carcinoma: An Italian Lung Cancer Project Observational Study. Cancer, 2003, 98: 128-134.
10. Xiang ZL, Wu Z, Zeng ZC, et al. Three dimensional-conformal radiotherapy combined with gemcitabine chemotherapy for locally advanced non-small lung cancer. Chin Clin Oncol (Chinese), 2006, 11:91-94.
11. Choy H. Chemoradiation in NSCLC: Focus on the role of gemcitabine. Oncology (Williston Park), 2004, 18(8 Suppl 5): 38-42.